Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865672 | 0.92 | DRD4 (0.65) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL4390012 | 0.92 | DRD4 (0.65) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL18658299 | 0.88 | SIGMAR1 (0.65) | SIGMAR1DRD3SLC6A12TMEM97MCHR1 | |
| SCHEMBL13003260 | 0.86 | SIGMAR1 (0.68) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL18658336 | 0.86 | SIGMAR1 (0.71) | SIGMAR1CHRM2CHRM1CHRM3KMT2A | |
| SCHEMBL6712413 | 0.85 | CHRM2 (0.66) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL14831782 | 0.84 | UBE2M (0.53) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL20179639 | 0.84 | CYP2D6 (0.50) | SIGMAR1CHRM2CHRM1CHRM3DRD4 | |
| SCHEMBL2425554 | 0.84 | SIGMAR1 (0.78) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL17294676 | 0.84 | CHRM3 (0.72) | SIGMAR1CHRM2CHRM1CHRM3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-6861423-B2 | Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds | SYNTEX (U.S.A.) LLC (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | SYNTEX (U.S.A) LLC | 2003-08-14 | — | — | US | disclosed |
| EP-1315726-A1 | 7- OXO PYRIDOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
| WO-2002018380-A1 | 7-OXO PYRIDOPYRIMIDINES AS INHIBITORS OF A CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000071171-A2 | SIGMA-1 LIGANDS FOR DETERMINING CARCINOMA PROLIFERATIVE STATUS | WAKE FOREST UNIVERSITY (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | SIGMAR1 2442/4885CHRM2 3694/4885CHRM1 3003/4885 |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | AR, PARP1, DPYD | SIGMAR1 2572/4885CHRM2 2534/4885CHRM1 1237/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | SIGMAR1 453/4885CHRM2 2186/4885CHRM1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.